PPFIA1 and CCND1 are frequently coamplified in breast cancer

Recently, amplification of PPFIA1, encoding a member of the liprin family located about 600 kb telomeric to CCND1 on chromosome band 11q13, was described in squamous cell carcinoma of head and neck. Because 11q13 amplification is frequent in breast cancer, and PPFIA1 has been suggested to contribute to mammary gland development, we hypothesized that PPFIA1 might also be involved in the 11q13 amplicon in breast cancer and contribute to breast cancer development. A tissue microarray containing more than 2000 human breast cancers was analyzed for gene copy numbers of PPFIA1 and CCND1 by means of fluorescence in situ hybridization. PPFIA1 amplification was found in 248/1583 (15.4%) of breast cancers. Coamplification with CCND1 was found in all (248/248, 100%) PPFIA1‐amplified cancers. CCND1 amplification without PPFIA1 coamplification was found in additional 117 (4.7%) tumors. Amplification of both PPFIA1 and CCND1 were significantly associated with high‐grade phenotype (P = 0.0002) but were unrelated to tumor stage (P = 0.7066) or nodal stage (P = 0.5807). No difference in patient prognosis was found between 248 CCND1/PPFIA1 coamplified tumors and 117 tumors with CCND1 amplification alone (P = 0.6419). These data show that PPFIA1 amplification occurs frequently in breast cancer. The higher incidence of CCND1 amplification when compared with PPFIA1, the lack of prognostic relevance of coamplifications, and the fact that PPFIA1 amplification was found exclusively in CCND1‐amplified cancers suggest that PPFIA1 gene copy number changes represent concurrent events of CCND1 amplification rather than specific biological incidents. © 2009 Wiley‐Liss, Inc.

[1]  F. Waldman,et al.  Chromosome 8p deletions are associated with invasive tumor growth in urinary bladder cancer. , 1997, The American journal of pathology.

[2]  D. Germain,et al.  Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3. , 2008, Cancer research.

[3]  L. Rydén,et al.  Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients , 2004, British Journal of Cancer.

[4]  Khee Chee Soo,et al.  Amplification and overexpression of PPFIA1, a putative 11q13 invasion suppressor gene, in head and neck squamous cell carcinoma , 2008, Genes, chromosomes & cancer.

[5]  M. Katoh,et al.  Comparative genomics on mammalian Fgf3-Fgf4 locus. , 2005, International journal of oncology.

[6]  I. Bièche,et al.  Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays , 2002, British Journal of Cancer.

[7]  O. Kallioniemi,et al.  Identification of target genes in laryngeal squamous cell carcinoma by high-resolution copy number and gene expression microarray analyses , 2006, Oncogene.

[8]  C. Serra-Pages,et al.  Liprins, a Family of LAR Transmembrane Protein-tyrosine Phosphatase-interacting Proteins* , 1998, The Journal of Biological Chemistry.

[9]  N. Guevara,et al.  Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: comparison with epidermal growth factor receptor status , 2008, British Journal of Cancer.

[10]  M. Kutty,et al.  Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters. , 2002, Oncology reports.

[11]  Robert L. Sutherland,et al.  Cyclin D1, EMS1 and 11q13 Amplification in Breast Cancer , 2003, Breast Cancer Research and Treatment.

[12]  R. Zeillinger,et al.  Cyclin gene amplification and overexpression in breast and ovarian cancers: Evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors , 1996, International journal of cancer.

[13]  F. Waldman,et al.  Patterns of p53, erbB-2, and EGF-r expression in premalignant lesions of the urinary bladder. , 1995, Human pathology.

[14]  Robert Maurer,et al.  High‐throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer , 2003, The Journal of pathology.

[15]  K. Kok,et al.  Amplicon Mapping and Expression Profiling Identify the Fas-Associated Death Domain Gene as a New Driver in the 11q13.3 Amplicon in Laryngeal/Pharyngeal Cancer , 2007, Clinical Cancer Research.

[16]  Alissa M. Weaver,et al.  Aggressiveness of HNSCC tumors depends on expression levels of cortactin, a gene in the 11q13 amplicon , 2008, Oncogene.

[17]  Y. Sagara,et al.  Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor‐negative breast cancer patients , 2002, International journal of cancer.

[18]  T. Hwang,et al.  Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients , 2003, Pathology international.

[19]  M. Fukumoto,et al.  Cyclin‐D1‐gene amplification is a more potent prognostic factor than its protein over‐expression in human head‐and‐neck squamous‐cell carcinoma , 1997, International journal of cancer.

[20]  A. Debant,et al.  The LAR transmembrane protein tyrosine phosphatase and a coiled‐coil LAR‐interacting protein co‐localize at focal adhesions. , 1995, The EMBO journal.

[21]  E. Montgomery,et al.  Expression profile and molecular genetic regulation of cyclin D1 expression in epithelioid sarcoma , 2005, Modern Pathology.

[22]  P. Lichter,et al.  Recurrent coamplification of cytoskeleton‐associated genes EMS1 and SHANK2 with CCND1 in oral squamous cell carcinoma , 2006, Genes, chromosomes & cancer.

[23]  K. Kok,et al.  High-resolution mapping identifies a commonly amplified 11q13.3 region containing multiple genes flanked by segmental duplications , 2007, Human Genetics.

[24]  H. Frierson,et al.  Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations. , 1993, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[25]  L. Skoog,et al.  Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer , 2007, Oncogene.

[26]  D. Birnbaum,et al.  Patterns of dna amplification at band q13 of chromosome 11 in human breast cancer , 1994, Genes, chromosomes & cancer.

[27]  M. Noguchi,et al.  Amplification of protooncogenes in surgical specimens of human lung carcinomas. , 1989, Cancer research.

[28]  Peter Schraml,et al.  Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer , 2004, Cancer Research.

[29]  H. Moch,et al.  Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. , 2001, Journal of the National Cancer Institute.

[30]  C. Serra-Pages,et al.  Liprin phosphorylation regulates binding to LAR: evidence for liprin autophosphorylation. , 2005, Biochemistry.

[31]  S. Elledge,et al.  Amplification of cyclin genes in colorectal carcinomas. , 1993, Cancer research.

[32]  D. Stacey,et al.  Variations in cyclin D1 levels through the cell cycle determine the proliferative fate of a cell , 2006, Cell Division.

[33]  K. Jirström,et al.  Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. , 2005, Cancer research.

[34]  R. Greil,et al.  Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy , 2008, Clinical Cancer Research.

[35]  R. Blamey,et al.  Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  G. Sauter,et al.  Tissue microarrays for comparing molecular features with proliferation activity in breast cancer , 2006, International journal of cancer.

[37]  Chenguang Wang,et al.  Minireview: Cyclin D1: normal and abnormal functions. , 2004, Endocrinology.